EUVIMEDEUVIMED entdecken
Crossref

Patterns of Treatment and Clinical Outcomes in Patients With Stage 1/2 EGFR-mutated Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Global, Multicenter, Retrospective Study

Steven H Lin, Kyoichi Okishio, Hideaki Mizutani, Jii Bum Lee, Sang-We Kim, Daniel Smith, Joel W Neal, Maximilian Hochmair, Keith L Davis, Maria Jimenez, Feruza Nasirova, YongJin Kim

International Journal of Radiation Oncology*Biology*Physics · 2026-11

DOI: 10.1016/j.ijrobp.2026.10.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-11. Verfasst von Steven H Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: shlin@mdanderson.org.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We report clinical outcomes, mutation testing patterns, and treatment patterns from a global, real-world, retrospective, observational study in patients with stage 1/2 epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Data were extracted from medical records of adults with stage 1/2 EGFR-mutated NSCLC (diagnosed January 2016-December 2019), who underwent stereotactic body radiation therapy (SBRT) as standard of care. The primary objective was assessment of real-world progression-free survival (rwPFS). Secondary objectives included assessment of mutation testing patterns, treatment sequencing post-SBRT, real-world time to next treatment or death (rwTTNTD), and real-world overall survival (rwOS). RESULTS: Data were extracted from medical records of 82 patients across six countries; 66% of patients had medically inoperable tumors; 43% had tumors harboring exon 19 deletion (Ex19del), 55% had L858R, 1% had both Ex19del and L858R, and 1% had L858R and an exon 20 insertion. Overall, 91% of patients had stage 1A/1B disease and 9% had stage 2A/2B. All patients underwent SBRT as standard of care; 31 patients (38%) progressed following SBRT. Of patients who received subsequent treatment (n = 25), most received EGFR-tyrosine kinase inhibitors (TKIs; 88%; n = 22/25); first-/second-generation EGFR-TKIs n=17, third-generation EGFR-TKIs n=5. Median (95% confidence interval [CI]) rwPFS, rwTTNTD, and rwOS were 47.1 (38.7-57.8), 49.8 (40.7-not estimable [NE]), and 62.9 (50.8-NE) months, respectively. The rwPFS rates at 12, 24, 36, 48, and 60 months (95% CI) were 90% (81-95), 76% (65-84), 65% (53-74), 48% (35-60), and 34% (19-48), respectively. CONCLUSIONS: In this global, real-world, retrospective study in patients with stage 1/2 EGFR-mutated NSCLC who underwent SBRT, the majority of whom had medically inoperable tumors, the 4-year rwPFS rate was

Schlagwörter

Stichwörter der Autor:innen

Non-small cell lung cancerSBRTmutation patternsreal-world studytreatment patterns

Autor:innen und Institutionen

  • Department of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: shlin@mdanderson.org.
  • Department of Thoracic Oncology, NHO, Kinki-Chuo Medical Center, Sakai, Japan.
  • Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University, Seoul, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Clinical Oncology, Guy's Cancer Centre, London, UK.

Zitieren

APA

Lin, S. H., Okishio, K., Mizutani, H., Lee, J. B., Kim, S. W., Smith, D., Neal, J. W., Hochmair, M., Davis, K. L., Jimenez, M., Nasirova, F., & Kim, Y. (2026). Patterns of Treatment and Clinical Outcomes in Patients With Stage 1/2 EGFR-mutated Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Global, Multicenter, Retrospective Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.10.034

Vancouver

Lin SH, Okishio K, Mizutani H, Lee JB, Kim SW, Smith D, et al. Patterns of Treatment and Clinical Outcomes in Patients With Stage 1/2 EGFR-mutated Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Global, Multicenter, Retrospective Study. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.10.034

BibTeX
@article{Lin2026,
  author = {Lin, Steven H and Okishio, Kyoichi and Mizutani, Hideaki and Lee, Jii Bum and Kim, Sang-We and Smith, Daniel and Neal, Joel W and Hochmair, Maximilian and Davis, Keith L and Jimenez, Maria and Nasirova, Feruza and Kim, YongJin},
  title = {Patterns of Treatment and Clinical Outcomes in Patients With Stage 1/2 EGFR-mutated Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Global, Multicenter, Retrospective Study},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2026.10.034}
}
Kostenlos starten →